Kintara suspends VAL-083 after GBM AGILE failure; Q1 net loss $3M, cash $0.2M

TuHURA Biosciences, Inc./NV

Topline GBM AGILE results showed VAL-083 did not perform better than standard of care; development suspended.
Focus shifts to REM-001 for cutaneous metastatic breast cancer; SBIR grant of $2.0M from NIH to support study.
Cash and cash equivalents $0.2M at Sep 30, 2023; raised ~$1.0M net in Nov 2023 via ATM facility.
Net loss $3.0M ($1.83/share) vs $4.6M ($3.39/share) in prior-year Q1; R&D and G&A expenses decreased.
Company evaluating strategic options to maximize shareholder value.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TuHURA Biosciences, Inc./NV reported fiscal first quarter ended September 30, 2023 results: net income approximately $3.0 million, or $1.83 per share, EPS $1.83 per share (basic and diluted loss per share from net loss attributable to common stockholders).

Period: fiscal first quarter ended September 30, 2023
Net income: approximately $3.0 million, or $1.83 per share
EPS: $1.83 per share (basic and diluted loss per share from net loss attributable to common stockholders)
Result: reported results

Exact text from the filing

For the three months ended September 30, 2023, Kintara reported a net loss of approximately $3.0 million, or $1.83 per share, compared to a net loss of approximately $4.6 million, or $3.39 per share, for the three months ended September 30, 2022.

View on SEC.gov

9 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-062968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.